In­tra-Cel­lu­lar shares mauled as a firestorm of spec­u­la­tion over ad­comm can­cel­la­tion spreads across BioTwit­ter

6 years ago
FDA+

FDA OKs Hu­mi­ra copy­cat from Mer­ck, Sam­sung Bioepis — but they will wait 4 years to launch

6 years ago
Pharma

Sharp­less out­lines FDA’s key pri­or­i­ties for ad­vanc­ing pub­lic health

6 years ago
FDA+

Cel­gene re­struc­tures a big Jounce pact, ze­ro­ing in on new I/O path­way with $530M deal — and bump­ing ICOS

6 years ago
Deals

Pro­teosta­sis shakes up med­ical team; No­vo funds an­tibi­otics ef­forts out of Curza, Spero

6 years ago
News Briefing

Stay tuned: Bio­gen’s num­bers are great — it’s their wor­ri­some fu­ture that leaves an­a­lysts skit­tish

6 years ago
R&D

PACT Phar­ma says it's per­fect­ed the tech to se­lect neoanti­gens for per­son­al­ized ther­a­py — now on­to the clin­ic

6 years ago
Discovery
Cell/Gene Tx

My­ovan­t's uter­ine fi­broid drug looks com­pet­i­tive in PhI­II — but can they van­quish mighty Ab­b­Vie?

6 years ago
R&D

Lit­tle Mar­i­nus sees its shares eclipsed as the Sage ri­val fails to com­pare on PPD in PhII

6 years ago
R&D

Fre­quen­cy fol­lows Astel­las pact with $62M round to bankroll PhII of lead re­gen­er­a­tive drug

6 years ago
Financing

3 years af­ter the FDA forced Chi­as­ma back in­to PhI­II, they’re back with pos­i­tive da­ta — but now they have a ri­val

6 years ago
R&D

Roche cuts loose Tam­i­flu OTC rights, hand­ing Sanofi the keys as the phar­ma gi­ant dou­bles down on Xofluza

6 years ago
Deals
Pharma

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

6 years ago
R&D
Pharma

Ver­tex gets NDA go­ing for CF triple com­bo; Dis­arm woos rare dis­ease ex­pert Alvin Shih as CEO

6 years ago
News Briefing

Take­da re­ports sec­ond PhI­II win for sub­cu­ta­neous En­tyvio as reg­u­la­tors re­view ex­pand­ed use

6 years ago
R&D
Pharma

FDA dis­cuss­es RWD, RWE with in­dus­try, acad­e­mia

6 years ago
FDA+

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

6 years ago
R&D
FDA+

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for ...

6 years ago
People
R&D

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks ...

6 years ago
Deals

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

6 years ago
R&D

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

6 years ago
Deals
Pharma

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

6 years ago
R&D

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

6 years ago
Pharma

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

6 years ago
Peer Review
First page Previous page 929930931932933934935 Next page Last page
A service from the Financial Times